Navigation Links
Covance Reports Fourth Quarter Pro Forma Net Revenue Of $561 Million, Pro Forma EPS Of $0.73 And Adjusted Net Orders Of $769 Million
Date:1/24/2013

eimbursable out-of-pocket expenses140,508140,508Total revenues2,236,446---2,236,446Costs and expenses:  Cost of revenue1,467,0511,467,051  Reimbursable out-of-pocket expenses140,508140,508  Selling, general and administrative343,044(22,592)(10,287)310,165  Depreciation and amortization105,214(1,777)103,437Total costs and expenses2,055,817(24,369)(10,287)-2,021,161Income from operations180,62924,36910,287-215,285Other expense, net:  Interest expense, net1,9791,979  Foreign exchange transaction loss, net1,2481,248  Impairment of equity investment12,119(12,119)-Other expense, net15,346-(12,119)-3,227Income before taxes and equity investee earnings165,28324,36922,406-212,058Tax expense33,5748,3023,1572,46947,502Equity investee earnings480480Net income $
32,189$
,067$
9,249$
(2,469)$
5,036Basic earnings per share$
2.22$
.27$
.32$
(0.04)$
2.77Weighted average shares outstanding - basic59,629,78859,629,78859,629,78859,629,78859,629,788Diluted earnings per share$
2.16$
.26$
.32$
(0.04)$
2.70Weighted average shares outstanding - diluted61,091,35461,091,35461,091,35461,091,35461,091,354(1) Represents costs incurred in connection with capacity rationalization, streamlining operations and other cost reduction actions.(2) Represents costs incurred in connection with termination of an inventory supply agreement and related inventory write-down and an impairment of a related equity investment.(3) Represents favorable resolutions of income tax matters. 


'/>"/>
SOURCE Covance Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Covance To Present At The William Blair 32nd Annual Growth Stock Conference
2. Covance Reports Second Quarter Pro Forma Net Revenue Of $538 Million, Pro Forma EPS Of $0.65 And Adjusted Net Orders Of $701 Million
3. Covance to Present at the Morgan Stanley Global Healthcare Conference
4. Covance Reports Third Quarter Pro Forma Net Revenue Of $542 Million, Pro Forma EPS Of $0.72 And Adjusted Net Orders Of $701 Million
5. Covance To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
6. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
7. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
8. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
9. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
10. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
11. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... July 2, 2015 According to a ... (Deep Brain Stimulation, Spinal Cord Stimulation, Transcranial Magnetic Stimulation), Application ... Forecast to 2020", published by MarketsandMarkets, the global Neuromodulation Market ... to reach $6.20 Billion by 2020, at a CAGR of ... 8 4 market data T ...
(Date:7/2/2015)... Numotion,s Board of Directors and Mike ... Feitel has joined the Company as Chief Financial ... successful 18 year career at GE serving in executive ... productivity to result in significant industry leading growth and ... Officer for GE Healthcare Global Services, a $5B P&L ...
(Date:7/2/2015)... , June 25, 2015 ... has announced the addition of the ... Immunodiagnostics: Global Challenges, Emerging Technologies, Competitive Landscape" ... 2015 New Frontiers in Clinical Chemistry and ... is a new seven-country strategic analysis of ...
Breaking Medicine Technology:Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4Numotion Names Tamas Feitel Chief Financial Officer 2New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2
... Dec. 6 Results from RESTORE 2, a,placebo-controlled, Phase ... the number of seizures in adult,patients with refractory partial-onset ... added to a patient,s current anti-epileptic drug (AED) therapy. ... experiencing,seizures despite taking stable doses of up to three ...
... - Results Presented at ASH Annual Meeting- , ... Sanofi-aventis today announced results of a randomized phase ... the American Society of Hematology. The study in adult ... for tumor lysis syndrome (TLS) demonstrated that Elitek(R) (rasburicase) ...
Cached Medicine Technology:Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 2Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 3Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 4Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 5Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 2Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 3Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 4Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 5
(Date:7/3/2015)... LENEXA, Kan. (PRWEB) , ... July 03, 2015 ... ... firm dedicated exclusively to healthcare providers, has been retained to lead a national ... the top-ranked executive search firms in the healthcare industry, B. E. Smith has ...
(Date:7/3/2015)... ... July 03, 2015 , ... Talcum powder attorneys representing clients in national lawsuits ... Cancer Lawsuit Center website. Just as the previous version did, the new website will ... lawsuit updates and ovarian cancer warning information. The site is routinely updated with news ...
(Date:7/3/2015)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... and expose popular lies regarding proper relationships according to the bible. , ... the core of the subject by explaining why certain types of sexual relationships are ...
(Date:7/2/2015)... ... ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest location in Dallas, ... The premium frozen yogurt chain was listed as #22 on the Inc. 500 list of ... at Bachman Lake, is located at:, 3701 W. Northwest Highway, STE 430, Dallas, TX 75220 ...
(Date:7/2/2015)... ... July 02, 2015 , ... When Walker Parking ... the University of Minnesota, they knew it would save the university energy and ... award-winning choice: the total energy savings after installation was an impressive 89 percent, ...
Breaking Medicine News(10 mins):Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2
... today announced,the release and first shipment of their marine-grade ... chair to oil and,gas platform operators in the Gulf ... platforms will enable the safe and timely evacuation of ... the dual-track MOV in response to the offshore,industry demands ...
... TAMPA, Fla., May 13 A complete review ... of a multi-disciplinary and,collaborative approach to weight loss, ... Clinics(R). The use of several proven,weight management strategies ... offer the greatest likelihood of success., NBC,s ...
... Performance during Sports or Play, CARLSBAD, Calif., May ... and retailer of custom-fitted arch supports and,natural sponge rubber ... of arch supports designed specifically for children ages 6 ... "SportFlex," are now,currently available at participating Good Feet Stores ...
... Israel, May 13 Lumenis Inc., a ... and radiofrequency,devices for surgical, aesthetic, and ophthalmic ... Laser Enucleation of the Prostate (HoLEP),preceptor program ... are interested in learning and performing HoLEP. ...
... 2008 Johnson & Johnson today announced that Professor ... Ravinder N. Maini, FRCP, FMedSci, FRS of the Kennedy ... the recipients of the 2008 Dr. Paul Janssen Award ... world-renowned scientists. , The award salutes the most ...
... Denmark, May 12, Warner Chilcott and LEO ... and Drug Administration (FDA) has approved the,New ... 0.005% and,betamethasone dipropionate 0.064%) Topical Suspension. LEO ... the FDA in July 2007. Taclonex Scalp(R) ...
Cached Medicine News:Health News:Research Converging in Favor of New Approach to U.S. Weight Problem 2Health News:Good Feet Announces New Arch Support Product Line for Children Ages 6 and Older 2Health News:Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting 2Health News:Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting 3Health News:Marc Feldmann and Sir Ravinder Maini win Dr. Paul Janssen Award for Biomedical Research 2Health News:Marc Feldmann and Sir Ravinder Maini win Dr. Paul Janssen Award for Biomedical Research 3Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 2Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 3Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 4
Inquire...
Inquire...
Hydragel K20 is Sebia's quality line of manual agarose gel electrophoresis products. Samples are applied utilizing the same patented applicator combs that is used for sample application on the HYDRAS...
... a new device for skin extension.Thanks to ... strips, it allows a constant and powerful ... other devices capacities. Such effectiveness makes the ... it is removed before 30 days. Furthermore ...
Medicine Products: